Top Penny Stocks To Watch In May 2025

In This Article:

As the U.S. stock market experiences a positive streak, with the Dow Jones and S&P 500 rising for the eighth consecutive day, investors are keenly observing how major tech earnings influence broader economic sentiment. Penny stocks, though often overlooked due to their historical connotations, remain relevant as potential investment opportunities in this dynamic landscape. These stocks typically represent smaller or newer companies and can offer unexpected growth potential when supported by strong financial fundamentals. In this article, we explore several penny stocks that may stand out for their financial robustness and long-term promise.

Top 10 Penny Stocks In The United States

Name

Share Price

Market Cap

Financial Health Rating

Safe Bulkers (NYSE:SB)

$3.39

$354.37M

★★★★☆☆

Tuya (NYSE:TUYA)

$2.35

$1.19B

★★★★★★

Smith Micro Software (NasdaqCM:SMSI)

$0.9894

$17.95M

★★★★☆☆

Kiora Pharmaceuticals (NasdaqCM:KPRX)

$3.30

$9.9M

★★★★★★

Flexible Solutions International (NYSEAM:FSI)

$3.77

$49.07M

★★★★★★

Waterdrop (NYSE:WDH)

$1.31

$481.01M

★★★★★☆

TETRA Technologies (NYSE:TTI)

$2.85

$367.28M

★★★★☆☆

BAB (OTCPK:BABB)

$0.819475

$5.97M

★★★★★★

Lifetime Brands (NasdaqGS:LCUT)

$3.625

$81.25M

★★★★★☆

CBAK Energy Technology (NasdaqCM:CBAT)

$0.785

$72.17M

★★★★★☆

Click here to see the full list of 754 stocks from our US Penny Stocks screener.

Let's explore several standout options from the results in the screener.

KORU Medical Systems

Simply Wall St Financial Health Rating: ★★★★★☆

Overview: KORU Medical Systems, Inc. develops, manufactures, and commercializes subcutaneous infusion solutions for the drug delivery market both in the United States and internationally, with a market cap of $126.38 million.

Operations: The company generates revenue of $33.65 million from its Surgical & Medical Equipment segment.

Market Cap: $126.38M

KORU Medical Systems, with a market cap of US$126.38 million, is navigating the penny stock landscape by focusing on strategic growth and financial stability despite current unprofitability. The company reported a net loss reduction to US$6.07 million for 2024 from US$13.74 million the previous year, signaling improved cost management. Recent developments include an extended credit facility with HSBC Ventures USA and an agreement with a global pharmaceutical firm to develop advanced infusion systems, potentially enhancing future revenue streams. KORU's experienced management and board support its strategic initiatives while maintaining sufficient cash runway for over three years.